GynecologyGynecology2079-56962079-5831Consilium Medicum8884610.26442/20795696.2021.6.201286Research ArticleResults of a clinical study of the drug efficacy and safety for intravesical administration based on bacteriophages in therapy in patients with chronic recurrent cystitisZaitsevAndrei V.<p>D. Sci. (Med.), Prof.</p>zaitcevandrew@mail.ruhttps://orcid.org/0000-0003-3044-1424ArefevaOksana A.<p>Cand. Sci. (Med.)</p>oksadoc@yandex.ruhttps://orcid.org/0000-0003-2309-2094SazononaNatalia A.<p>Graduate Student</p>natsazonova@outlook.comhttps://orcid.org/0000-0003-1673-1089MelnikovVladimir D.<p>Graduate Student</p>vladimir-m95@mail.ruhttps://orcid.org/0000-0002-2403-4331KimYuriy A.<p>Graduate Student</p>dockimyura@gmail.comhttps://orcid.org/0000-0001-6390-3408ShiryaevArseniy A.<p>Graduate Student</p>eschief2@gmail.comhttps://orcid.org/0000-0003-0680-9460VasilyevAlexander O.<p>Cand. Sci. (Med.)</p>alexvasilyev@me.comhttps://orcid.org/0000-0001-5468-0011GritskovIgor O.<p>Resident</p>grickoff@mail.ruhttps://orcid.org/0000-0002-4708-1683GovorovAlexander V.<p>D. Sci. (Med.), Prof.</p>dr.govorov@gmail.comhttps://orcid.org/0000-0003-3299-0574PushkarDmitry Yu.<p>D. Sci. (Med.), Prof., Acad. RAS</p>pushkardm@mail.ruhttps://orcid.org/0000-0002-6096-5723Yevdokimov Moscow State University of Medicine and DentistrySpasokukotsky City Clinical HospitalResearch Institute of Health Organization and Medical Management1512202123657858522112021Copyright © 2021, Consilium Medicum2021<p><strong>Background. </strong>Urinary tract infections remain one of the urgent problems in the aspect of qualified medical care. The causative agents of nosocomial infections are becoming more and more resistant to the drugs used, while the rate of new drugs synthesis is lower than the rate of development of antibiotic resistance. Routine and empirical prevention of recurrent urinary tract infections is often ineffective.</p>
<p><strong>Aim. </strong>To study the efficacy and safety of intravesical application of the drug based on bacteriophages in therapy in patients with chronic recurrent cystitis.</p>
<p><strong>Materials and methods. </strong>A clinical study was carried out to study the efficacy and safety of the drug for intravesical administration based on bacteriophages in therapy in patients with chronic recurrent cystitis. The study included 75 patients who were divided into 3 groups in a 1: 1: 1 ratio. In the main group, the drug for intravesical administration based on bacteriophages, as well as rectal suppositories with bacteriophages were used; in the control group only a drug for intravesical administration based on bacteriophages or rectal suppositories with bacteriophages. On visits 1-4, all patients underwent a clinical blood test, general urine analysis, bacteriological urine analysis, as well as urine analysis by the polymerase chain reaction method. The analysis of the patients condition in groups was carried out according to the dynamics of main clinical symptoms changes, data from validated scales for assessing pelvic pain and urgency/frequency of urination and assessment of symptoms of acute cystitis (Acute Cystitis Symptom Score ACSS), as well as the dynamics of changes in objective parameters of laboratory studies and possible changes in sensitivity uropathogens to antibacterial drugs.</p>
<p><strong>Results. </strong>The average age of the patients included in the study was 50.6 years. In all 3 groups, bacteriological examination of urine showed a predominant growth of <em>Escherichia coli</em> (310<sup>4</sup> CFU/ml). In the course of the study, there was a good tolerance to therapy, a decrease in clinical symptoms, as well as a significant decrease in the total score according to the pelvic pain scale and urgency/frequency of urination and the ACSS scale in all patients.</p>
<p><strong>Conclusion. </strong>The emergence of a large number of microorganisms resistant to various antibiotics and their rapid spread in the environment has led to an increase in scientific interest in bacteriophage therapy as an alternative method of treatment. The overall subjective effectiveness of the therapy in our study was more than 80%, safety - 100%. Further research will allow for a personalized approach to the treatment of infectious diseases of the urinary system.</p>bacteriophagesantibiotic resistancelower urinary tract infectionsrecurrent cystitisphage therapyбактериофагиантибиотикорезистентностьинфекции нижних мочевыводящих путейрецидивирующий циститфаготерапия[Tandogdu Z, Wagenlehner FME. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29(1):73-9. DOI:10.1097/QCO.0000000000000228][Ikäheimo R, Siitonen A, Heiskanen T, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis. 1996(22):91-9. DOI:10.1093/clinids/22.1.91][Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J Urol. 2005;173:1281-7. DOI:10.1097/01.ju.0000155596.98780.82][Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol. 2000;151(12):1194-205. DOI:10.1093/oxfordjournals.aje.a010170][Magistro G, Marcon J, Schubert S, et al. Pathogenese der harnwegsinfektion ein update. Der Urologe. 2017;56(6):720-7. DOI:10.1007/s00120-017-0391-7][Hooton TM, Scholes D, Hughes JP. A prospective study of risk factors for symptomatic urinary tract infection in young women. New Engl J Med. 1996;335(7):468-74. DOI:10.1056/NEJM199608153350703][Scholes D, Hawn TR, Roberts PL, et al. Family history and risk of recurrent cystitis and pyelonephritis in women. J Urol. 2010;184(2):564-9. DOI:10.1016/j.juro.2010.03.139][Hooton TM, Stapleton AE, Roberts PL Perineal anatomy and urine-voiding characteristics of young women with and without recurrent urinary tract infections. Clin Infect Dis. 1999;29(6):1600-1. DOI:10.1086/313528][Albert X, Huertas I, Pereiro´ II, et al. Antibiotics for preventing recurrent urinary tract infection in nonpregnant women. Cochrane Database Syst Rev. 2004;2004:CD001209. DOI;10.1002/14651858.CD001209.pub2][Ny S, Edquist P, Dumpis U, et al. Antimicrobial resistance of Escherichia coli isolates from outpatient urinary tract infections in women in six European countries including Russia. J Glob Antimicrob Resist. 2019;17:25-34. DOI:10.1016/j.jgar.2018.11.004][Wojno KJ, Baunoch D, Luke N, et al. Multiplex PCR Based Urinary Tract Infection (UTI) Analysis Compared to Traditional Urine Culture in Identifying Significant Pathogens in Symptomatic Patients. Urology. 2020;136:119-26. DOI:10.1016/j.urology.2019.10.018][Lee SJ, Choe HS, Na YG. Guidelines of the Korean association of urogenital tract infection and inflammation: recurrent urinary tract infection. Urogenit Tract Infect. 2017;12(1):7. DOI:10.14777/uti.2017.12.1.7][Hooton TM, Vecchio M, Iroz A, et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections: a randomized clinical trial. JAMA Intern Med. 2018;178(11):1509-15. DOI:10.1001/jamainternmed.2018.4204][Finh SD, Boyko EJ, Normand EH, et al. Association between use of spermicide-coated condoms and escherichia coli urinary tract infection in young women. Am J Epidemiol. 1996;144(5):512-20. DOI:10.1093/oxfordjournals.aje.a008958][Schmidt DR, Sobota AE. An examination of the anti-adherence activity of cranberry juice on urinary and nonurinary bacterial isolates. Microbios. 1988;55(224-225):173-81.][Stapleton AE, Dziura J, Hooton TM, et al. Recurrent urinary tract infection and urinary escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo Clin Proc. 2012;87(2):143-50. DOI:10.1016/j.mayocp.2011.10.006][Beerepoot MAJ, ter Riet G, Nys S, et al. Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. Arch Intern Med. 2011;171(14):1270-8. DOI:10.1001/archinternmed.2011.306][Avorn J, Monane M, Gurwitz JH, et al. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA. 1994;271(10):751-4. DOI:10.1001/jama.1994.03510340041031][Lenger SM, Bradley MS, Thomas DA, et al. D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis. Am J Gynecol. 2020;223(2):265.e1-265.e13. DOI:10.1016/j.ajog.2020.05.048][Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32(1):79-84. DOI:10.1007/s00345-013-1091-6][Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urology. 2011;59(4):645-51. DOI:10.1016/j.eururo.2010.12.039][Interdisziplinäre S3 leitlinie: epidemiologie, diagnostik, therapie, prevention und management unkomplizierter, bakterieller, ambulant erworbener harnwegsinfektionen bei erwachsenen patienten. AWMF-Register-Nr. 043/044 2017 (Version 1.1-2).][Botros C, Lozo S, Iyer S, et al. Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial. Int Urogynecol J. 2021. DOI:10.1007/s00192-021-04849-0][Larsson B, Jonasson A, Fianu S. Prophylactic effect of UVA-E in women with recurrent cystitis: a preliminary report. Curr Ther Res. 1993;53(4):441-3. DOI:10.1016/S0011-393X(05)80204-8][Albrecht U, Goos K-H, Schneider B. A randomised, double-blind, placebo-controlled trial of a herbal medicinal product containing Tropaeoli majoris herba (Nasturtium) and Armoraciae rusticanae radix (Horseradish) for the prophylactic treatment of patients with chronically recurrent lower urinary tract infections. Curr Med Res Opin. 2007;23(10):2415-22. DOI:10.1185/030079907X233089][Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. New Engl J Med. 1993(329):753-6. DOI:10.1056/NEJM199309093291102][Eriksen BC. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999;180(5):1072-9. DOI:10.1016/s0002-9378(99)70597-1][Raz R, Colodner R, Rohana Y, et al. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin Infect Dis. 2003;36(11):1362-8. DOI:10.1086/374341][Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS. Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: a meta-analysis of five placebo-controlled double-blind studies. Int J Antimicrob Agents. 2002;19(6):451-6. DOI:10.1016/s0924-8579(02)00106-1][Nestler S, Grüne B, Schilchegger L, et al. Efficacy of vaccination with StroVac for recurrent urinary tract infections in women: a comparative single-centre study. Int Urol Nephrol. 2021;53(11):2267-72. DOI:10.1007/s11255-021-02987-4][Clarke AL, Soir S de, Jones JD. The safety and efficacy of phage therapy for bone and joint infections: a systematic review. Antibiotics (Basel, Switzerland). 2020;9(11):795. DOI:10.3390/antibiotics9110795.][Gibb BP, Hadjiargyrou M. Bacteriophage therapy for bone and joint infections. Bone Joint J. 2021;103-B(2):234-44. DOI:10.1302/0301-620X.103B2.BJJ-2020-0452.R2][Leitner L, Ujmajuridze A, Chanishvili N, et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021;21(3):427-36. DOI:10.1016/S1473-3099(20)30330-3][Bao Y, Al KF, Chanyi RM, et al. Questions and challenges associated with studying the microbiome of the urinary tract. Ann Transl Med. 2017;5(2):33. DOI:10.21037/atm.2016.12.14][Yilmaz S, Allgaier M, Hugenholtz P. Multiple displacement amplification compromises quantitative analysis of metagenomes. Nat Methods. 2010;7(12):943-4. DOI:10.1038/nmeth1210-943][Panek M, Cipcic Paljetak H, Baresic A, et al. Methodology challenges in studying human gut microbiota – effects of collection, storage, DNA extraction and next generation sequencing technologies. Sci Rep. 2018;8(1):5143. DOI:10.1038/s41598-018-23296-4][Brubaker L, Wolfe A. The urinary microbiota: a paradigm shift for bladder disorders? Curr Opin Obstet Gynecol. 2016;28(5):407-12. DOI:10.1097/GCO.0000000000000298][Santiago-Rodriguez TM, Ly M, Bonilla N, Pride DT. The human urine virome in association with urinary tract infections. Front Microbiol. 2015;6:14. DOI:10.3389/fmicb.2015.00014][Malki K, Shapiro JW, Price TK, et al. Genomes of gardnerella strains reveal an abundance of prophages within the bladder microbiome. PLoS One. 2016;11(11):e0166757. DOI:10.1371/journal.pone.0166757][Miller-Ensminger T, Garretto A, Brenner J, et al. Bacteriophages of the urinary microbiome. J Bacteriol. 2018;200(7):e00738-17. DOI:10.1128/JB.00738-17][Moustafa A, Li W, Singh H, et al. Microbial metagenome of urinary tract infection. Sci Rep. 2018;8(1):4333. DOI:10.1038/s41598-018-22660-8]